Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody–associated vasculitis
Arthritis & Rheumatism2005Vol. 52(1), pp. 262–268
Citations Over TimeTop 1% of 2005 papers
Abstract
The ability to achieve stable remissions with rituximab in patients with AAV refractory to conventional therapy suggests that B lymphocyte depletion may be a safe, effective, mechanism-based treatment modality for treatment of patients with these conditions.
Related Papers
- → Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?(2007)170 cited
- → Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome(2015)43 cited
- Cytoplasmic antineutrophil cytoplasmic antibody-positive vasculitis associated with ulcerative colitis.(1997)
- [Relationship between methimazole and antineutrophil cytoplasmic antibody-positive vasculitis].(2008)
- → Perinuclear–antineutrophil cytoplasmic antibodies are associated with vasculitis(2001)2 cited